Sphingobacterium respiratory tract infection in patients with cystic fibrosis

BMC Research Notes

Volumn 2, Issue , 2009, Pages

  Lambiase, Antonietta ^a   Rossano, Fabio ^a   Del Pezzo, Mariassunta ^a   Raia, Valeria ^a   Sepe, Angela ^a   De Gregorio, Fabiola ^a   Catania, Maria ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BACILLI (CLASS); BACTERIA (MICROORGANISMS); NEGIBACTERIA; SPHINGOBACTERIUM; SPHINGOBACTERIUM MULTIVORUM;

EID: 77049113297     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-2-262     Document Type: Article

References (23)

1. Management of pulmonary disease in patients with cystic fibrosis. Ramsey BW, N Eng J Med 1996 335 179 188 10.1056/NEJM199607183350307 (Pubitemid 26249456)
2. Microbiology of airway diseases in patients with cystic fibrosis. Gilligan PH, Clin Microbiol Rev 1991 4 35 51 1900735
3. Stenotrophomonas maltophilia in cystic fibrosis: incidence and prevalence. Demko CA Stern RC Doershunk CF., Pediatr Pulmonol 1998 25 304 308 10.1002/(SICI)1099-0496(199805)25:5<304::AID-PPUL3>3.0.CO;2-I 9635931
4. Microbiology of airway disease in a cohort of patients with Cystic Fibrosis. Lambiase A Raia V, Del Pezzo M Sepe A, Carnovale V Rossano F, BMC Infect Dis 2006 6 4 10.1186/1471-2334-6-4 16405721
5. Nontuberculous mycobacterial pulmonary diseases in cystic fibrosis. Olivier K Yankaskas JR Knowles MR., Semin Respir Infect 1996 11 272 284 8976581
6. Molecular epidemiology of Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans in a cystic fibrosis centre. Vu-Thien H Moissenet D, Valcin M Dulot C, Tournier G Garbarg-Chenon A, Eur J Clin Microbiol Infect Dis 1996 15 249 260 10.1007/BF01691221
7. Burkholderia respiratory tract infections in Italian patients with cystic fibrosis: Molecular characterization. Allice T Scutera S, Chirillo MG Savoia D, J Infect 2006 53 159 165 10.1016/j.jinf.2005.11.005 16375971
8. Achromobacter xylosoxidans respiratory tract infections in cystic fibrosis patiernts. Raso T Bianco O Grosso B Zucca M, Savoia D., APMIS 2008 118 837 841 10.1111/j.1600-0463.2008.00995.x
9. Septicemia caused by Sphingobacterium multivorum. Freney J Hansen W Ploton C Meugnier H, Madier S Bornstein N, Fleurette J., J Clin Microbiol 1987 25 1126 1128 3597758
10. Flavobacterium spiritovorum, a new species isolated from human clinical specimens. Holmes B Owen RJ Hollis DG., Int J Syst Bacteriol 1982 32 157 165
11. Flavobacterium multivorum, a new species isolated from human clinical specimens and previously known as group IIk biotype 2. Holmes B Owen RJ Weaver R., Int J Syst Bacteriol 1981 31 21 34
12. Sphingobacterioum multivorum isolated from a patient with cystic fibrosis. Reina J Borrel N Figuerola J., Eur J Clin Microbiol Infect Dis 1992 11 81 82 10.1007/BF01971283 1563393
13. Structural analysis of sphingophospholipids derived from Sphingobacterium spiritovorum, the type species of genus Sphingobacterium. Naka T Fujiwara N, Yano I Maeda S, Doe M Minamino M, Ikeda N Kato Y, Watabe K Kumazawa Y, Tomiyasu I Kobayashi K, Biochim Biophys Acta 2003 1635 83 92 14729071
14. Changing epidemiology of Pseudomonas aeruginosa infection in Danish Cystic Fibrosis patients (1974-1995). Frederiksen B Koch C Høoiby N., Pediatr Pulmunol 1999 28 159 166 10.1002/(SICI)1099-0496(199909)28:3<159:: AID-PPUL1>3.0.CO;2-1 (Pubitemid 29420280)
15. The microbiological basis for antimicrobial therapy. Saiman L MacDonald NE Whittier S., Tenth Annual North American Cystic Fibrosis Conference. Cystic Fibrosis Foundation 1996
16. Sphingobacterium gen. nov., Sphingobacterium spiritovorum comb. Nov., Sphingobacterium multivorum comb. Nov., Sphingobacterium mizutae sp. Nov., and Flavobacterium indologenes sp. Nov.: glucose-nonfermenting gram-negative rods in CDC groups IIK-2 and IIb. Yabuuchi E Kaneko T Yano I Moss CW, Miyoshi N., Int J Syst Bacteriol 1983 33 580 598
17. Enzymatic profile of Pseudomonas maltophilia. O'Brien M Davis GH, J Clin Microbiol 1982 16 417 421 6813350
18. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, Approved standard M7-A5. National Committee for Clinical Laboratory Standards, National Committee for Clinical Laboratory Standards, Wayne, PA 5 2002
19. Genome fingerprinting of Pseudomonas aeruginosa indicates colonization of Cystic Fibrosis siblings with closely related strains. Grothues D Koopmann U, Hardt, Van der H Tummler B J Clin Microbiol 1988 26 115 123
20. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. Tenover F Arbeit R Goering R Mickelsen P, Murray B Persing D, Swaminathan B., J Clin Microbiol 1995 33 2233 2239 7494007
21. Characterization of unusual bacteria isolated from respiratory secretions of Cystic Fibrosis patients and description of Inquilinus limosus gen. nov., sp. nov. Coenye T Goris J Spilker T Vandamme P, Lipuma JJ., J Clin Microbiol 2002 40 2062 2069 10.1128/JCM.40.6.2062-2069.2002 12037065
22. Identification and antimicrobial susceptibility of Alcaligenes xylosoxidans isolated from patients with Cystic Fibrosis. Saiman L Chen Y, Tabibi S San Gabriel P, Zhou J Liu Z, Lai L Whittier S, J Clin Microbiol 2001 39 3942 3945 10.1128/JCM.39.11.3942-3945.2001 11682511
23. Bacteriemia caused by a novel species of Sphingobacterium. Tronel H Plesiat P, Ageron E Grimont PAD, Clin Microbiol Infect 2003 9 1242 1244 10.1111/j.1469-0691.2003.00801.x 14686992